The stock of Gilead Sciences, Inc. (GILD) has gone up by 1.43% for the week, with a -2.31% drop in the past month and a -0.46% drop in the past quarter. The volatility ratio for the week is 1.79%, and the volatility levels for the past 30 days are 1.91% for GILD. The simple moving average for the last 20 days is -2.17% for GILD stock, with a simple moving average of -3.59% for the last 200 days.

Is It Worth Investing in Gilead Sciences, Inc. (NASDAQ: GILD) Right Now?

The price-to-earnings ratio for Gilead Sciences, Inc. (NASDAQ: GILD) is above average at 16.30x. The 36-month beta value for GILD is also noteworthy at 0.31.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The public float for GILD is 1.25B, and at present, short sellers hold a 1.57% of that float. The average trading volume of GILD on November 21, 2023 was 5.62M shares.

GILD) stock’s latest price update

The stock of Gilead Sciences, Inc. (NASDAQ: GILD) has increased by 0.73 when compared to last closing price of 75.45. Despite this, the company has experienced a 1.43% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-20 that We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Analysts’ Opinion of GILD

Many brokerage firms have already submitted their reports for GILD stocks, with Deutsche Bank repeating the rating for GILD by listing it as a “Hold.” The predicted price for GILD in the upcoming period, according to Deutsche Bank is $75 based on the research report published on November 09, 2023 of the current year 2023.

GILD Trading at -1.07% from the 50-Day Moving Average

After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.31% of loss for the given period.

Volatility was left at 1.91%, however, over the last 30 days, the volatility rate increased by 1.79%, as shares sank -2.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.35% lower at present.

During the last 5 trading sessions, GILD rose by +1.43%, which changed the moving average for the period of 200-days by -10.06% in comparison to the 20-day moving average, which settled at $77.61. In addition, Gilead Sciences, Inc. saw -11.47% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GILD starting from Dickinson Andrew D, who sale 5,000 shares at the price of $80.00 back on Oct 17. After this action, Dickinson Andrew D now owns 104,003 shares of Gilead Sciences, Inc., valued at $400,017 using the latest closing price.

Parsey Merdad, the Chief Medical Officer of Gilead Sciences, Inc., sale 1,501 shares at $76.99 during a trade that took place back on Sep 12, which means that Parsey Merdad is holding 70,130 shares at $115,562 based on the most recent closing price.

Stock Fundamentals for GILD

Equity return is now at value 27.08, with 9.41 for asset returns.


In summary, Gilead Sciences, Inc. (GILD) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.